All News

PsA.Hands_.jpg

ICYMI: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis

d Jack Cush, MD

An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab on top of methotrexate to reach minimal disease activity (MDA) response. 

Read Article
CSS Storm Cytokine

Rheumatic Associated Macrophage Activation Syndrome

d Jack Cush, MD

Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and may arise in patients with rheumatic disease.

Read Article
infusion.biologic.jpg

ICYMI: Drug Survival Differences in RA, PsA, SpA and PsO

d Jack Cush, MD

Drug survival may be the best measure of efficacy and safety. A study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.

Read Article
renal.stone_.LBP_.jpg

ICYMI: Allopurinol Safety in CKD Patients

d Jack Cush, MD

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
Axial Spondyloarthritis

ICYMI: Update on Axial SpA at EULAR 2022

d Antoni Chan, MD, PhD

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 #MedTwitter https://t.co/xUkQmwoeni
Dr. John Cush RheumNow ( View Tweet)
Single center comparison of MAS (n 18) to malignancy related mHLH (n = 16). Notable differences seen in platelet (lower in mHLH 29k v 50K), soluble IL-2R (6814 vs 27972), but more hepatomegaly (25% v 0). Less mortality with MAS (22 v 44%, p 0.18) https://t.co/gYdRfxDM2c https://t.co/ekMJfnzElC

Links:

Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/DyVCxDVPE7 https://t.co/PF7zqxX7yk

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b) https://t.co/ex231f27rg https://t.co/tjsra4blBi

Links:

Dr. John Cush RheumNow ( View Tweet)
Babies! Safety and Outcomes Data on Pregnancies #EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye... https://t.co/piA1zhGyAA https://t.co/Kb68AGZgA1

Links:

Dr. John Cush RheumNow ( View Tweet)
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/NEZDB20OXN https://t.co/4123Gh2v2Y

Links:

Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022. https://t.co/oa619uNgnB https://t.co/gyNnsMDXGo

Links:

Dr. John Cush RheumNow ( View Tweet)
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. https://t.co/0lcYkjFj3D
Dr. John Cush RheumNow ( View Tweet)
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis https://t.co/UisuOOABxG #EULAR2022 https://t.co/Og8opUJO2h

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/5EKmvIwTpV https://t.co/nh2bNkSp8G

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush RheumNow ( View Tweet)
Adults with JIA: It ain’t all child’s play https://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast up—“What Worries You, Masters You” We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed. https://t.co/jRaLCQAt9K https://t.co/opa22JqU41

Links:

Dr. John Cush RheumNow ( View Tweet)
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×